The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Institution: The Royal Melbourne Hospital ASH 2025 | Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated results from an ongoing Phase II trial (NCT04419649) of elritercept in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence. Dr Chee reports encouraging outcomes, which have led to the initiation of a Phase III trial. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
